Status:
TERMINATED
Evaluation of Brain Neurotransmitter Levels in Adults With ADHD, Before and After Stimulant Treatment
Lead Sponsor:
Weizmann Institute of Science
Collaborating Sponsors:
Tel Aviv University
Maccabi Healthcare Services, Israel
Conditions:
Attention Deficit Disorder With Hyperactivity
Eligibility:
All Genders
18-40 years
Phase:
NA
Brief Summary
Background: Attention deficit hyperactivity disorder (ADHD) is one of the most prevalent neurobiological brain disorders. Diagnosis of ADHD in adults is complex and subjective. Recent studies give fu...
Detailed Description
Hypothesis: 1. We hypothesize that brain Glu and GABA levels and/or their ratio involved in ADHD pathology 2. Glu and GABA levels and/or their ratio will be affected by medical treatment in ADHD grou...
Eligibility Criteria
Inclusion
- Giving informed written consent to participate on a voluntary basis.
- For the healthy control group:
- Men and women aged 18-40 years, who did not report ADHD or any other chronic or psychiatric illness or medical conditions (at most two symptoms of inattention and/or hyperactivity/impulsivity).
- For the ADHD group patients:
- Men and women aged 18-40 years, who have a diagnosis of ADHD, according to DSM V criteria by a Neurologist.
- Have a valid prescription for Mixed Amphetamine salts (Attent) or short-acting methylphenidate (Ritalin) for ADHD
- Withhold medication 72h prior to MRS scan.
Exclusion
- Exclusion criteria identical for patients and control group:
- Subjects with metallic devices that precludemagnetic resonance imaging or any silver part that is not MRI compliant
- Current presence of any other DSM V psychiatric disorder
- Significant medical or neurological illness affecting brain function
- Subjects with any clinically significant or unstable medical conditions
- Use of any psychotropic medication, other than stimulants, in the previous 3 months
- Pregnant women
- BMI \> 35
- History of brain MRI
- A patient who does not agree that the scan will be decoded by a radiologist
- A patient who does not agree that in case of an abnormal finding, the imaging results will be forwarded to the attending physician for further clarification
- Understanding and/or language problems
Key Trial Info
Start Date :
July 11 2024
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 11 2024
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT04823364
Start Date
July 11 2024
End Date
July 11 2024
Last Update
July 15 2024
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Maccabi Health Services
Kfar Saba, Israel
2
Weizmann
Rehovot, Israel